iifl-logo

Neuland Laboratories Ltd Half Yearly Results

16,846
(3.46%)
Nov 25, 2025|12:00:00 AM

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Financials

Particulars (Rupees in Crores.)Sept-2025Mar-2025Sept-2024Mar-2024Sept-2023

Gross Sales

807.03

726.39

750.45

777.84

780.74

Excise Duty

0

0

0

0

0

Net Sales

807.03

726.39

750.45

777.84

780.74

Other Operating Income

0

0

0

0

0

Other Income

9.66

67.15

29.77

7.46

5.09

Total Income

816.68

793.54

780.21

785.3

785.83

Total Expenditure

616.99

588.72

564.86

549.66

546.34

PBIDT

199.69

204.82

215.35

235.64

239.49

Interest

9.95

4.56

3.73

7.35

6.65

PBDT

189.74

200.26

211.62

228.29

232.85

Depreciation

42.73

33.19

32.35

31.61

28.09

Minority Interest Before NP

0

0

0

0

0

Tax

36.88

30.97

42.79

47.28

52.39

Deferred Tax

-0.63

6.7

5.76

0.45

1.24

Reported Profit After Tax

110.75

129.39

130.72

148.95

151.13

Minority Interest After NP

0

0

0

0

0

Net Profit after Minority Interest

110.75

129.39

130.72

148.95

151.13

Extra-ordinary Items

0

55.78

15.04

0

0

Adjusted Profit After Extra-ordinary item

110.75

73.61

115.68

148.95

151.13

EPS (Unit Curr.)

86.32

100.3

101.88

115.46

117.79

Book Value (Unit Curr.)

0

0

0

0

0

Dividend (%)

0

0

0

0

0

Equity

12.9

12.9

12.9

12.9

12.9

Public Shareholding (Number)

0

0

0

0

0

Public Shareholding (%)

0

0

0

0

0

Pledged/Encumbered - No. of Shares

0

0

0

0

0

Pledged/Encumbered - % in Total Promoters Holding

0

0

0

0

0

Pledged/Encumbered - % in Total Equity

0

0

0

0

0

Non Encumbered - No. of Shares

0

0

0

0

0

Non Encumbered - % in Total Promoters Holding

0

0

0

0

0

Non Encumbered - % in Total Equity

0

0

0

0

0

PBIDTM(%)

24.74

28.19

28.69

30.29

30.67

PBDTM(%)

-

-

-

-

-

PATM(%)

13.72

17.81

17.41

19.14

19.35

Neuland Labs.: Related NEWS

Neuland Laboratories tumbles ~7% as 3.8% shares change hands

The transaction takes place against the backdrop of a more than 9% reduction in the stock's value during the previous week.

12 Dec 2024|02:19 PM
Read More
Neuland Laboratories gets USFDA approval for Schizophrenia Drug

However, it is unclear whether the Hyderabad-based company will be Cobenfy's exclusive supplier.

27 Sep 2024|03:17 PM
Read More

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Knowledge Center
Logo

Logo IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000

Logo IIFL Capital Services Support WhatsApp Number
+91 9892691696

Download The App Now

appapp
Loading...

Follow us on

facebooktwitterrssyoutubeinstagramlinkedintelegram

2025, IIFL Capital Services Ltd. All Rights Reserved

ATTENTION INVESTORS

RISK DISCLOSURE ON DERIVATIVES

Copyright © IIFL Capital Services Limited (Formerly known as IIFL Securities Ltd). All rights Reserved.

IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016, BSE Enlistment Number (RA): 5016
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor), PFRDA Reg. No. PoP 20092018

ISO certification icon
We are ISO 27001:2013 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.